Chemistry: analytical and immunological testing – Test for named disease – body condition or organ function
Reexamination Certificate
2010-10-28
2011-12-27
Yu, Melanie J (Department: 1641)
Chemistry: analytical and immunological testing
Test for named disease, body condition or organ function
C435S007920
Reexamination Certificate
active
08084276
ABSTRACT:
Described herein are methods for identifying a subject at risk of progression of heart failure. In some embodiments, the level of galectin-3 in a biological sample from a human subject may be measured and compared to a standard level indicative of risk of progression of heart failure, wherein an elevated level of galectin-3 in the sample indicates a risk of progression of heart failure.
REFERENCES:
patent: 4632901 (1986-12-01), Valkirs et al.
patent: 4704692 (1987-11-01), Ladner
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5132405 (1992-07-01), Huston et al.
patent: 6319676 (2001-11-01), Nazareth et al.
patent: 6485982 (2002-11-01), Charlton
patent: 6534322 (2003-03-01), Sabbadini
patent: 6889083 (2005-05-01), Kleckner et al.
patent: 2002/0076738 (2002-06-01), Woo
patent: 2003/0032030 (2003-02-01), Prolla et al.
patent: 2003/0166017 (2003-09-01), McCarthy
patent: 2004/0110221 (2004-06-01), Twine et al.
patent: 2005/0084915 (2005-04-01), Woo
patent: 2005/0106100 (2005-05-01), Harris et al.
patent: 2006/0019235 (2006-01-01), Soen et al.
patent: 2006/0019890 (2006-01-01), Kapoun et al.
patent: 2006/0141493 (2006-06-01), West et al.
patent: 2006/0166276 (2006-07-01), Doyle et al.
patent: 2006/0246496 (2006-11-01), Ahmed et al.
patent: 2006/0257946 (2006-11-01), Ding et al.
patent: 2007/0082332 (2007-04-01), Mendrick et al.
patent: 2007/0092886 (2007-04-01), Tabibiazar et al.
patent: 2007/0105105 (2007-05-01), Clelland et al.
patent: 2007/0274959 (2007-11-01), Zeiher et al.
patent: 2010/0014954 (2010-01-01), Henderson
patent: 2010/0143954 (2010-06-01), Muntendam
patent: 2011/0071583 (2011-03-01), Muntendam
patent: WO-0157274 (2001-08-01), None
patent: WO-0177389 (2001-10-01), None
patent: WO-03031650 (2003-04-01), None
patent: WO-03071279 (2003-08-01), None
patent: WO-2004038376 (2004-05-01), None
patent: WO-2004048933 (2004-06-01), None
patent: WO-2004063334 (2004-07-01), None
patent: WO-2004111654 (2004-12-01), None
patent: WO-2005023314 (2005-03-01), None
patent: WO-2005070446 (2005-08-01), None
patent: WO-2006026074 (2006-03-01), None
patent: WO-2006083986 (2006-08-01), None
Almkvist et al. (2004) “Galectins as inflammatory mediators,”Glyconconj J. 19:575-581.
Cooper (2002) “Galectinomics: Finding themes in complexity,”Biochim Biophys Acta. 1572:209-231.
Hsu et al. (1999) “Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma,”Int J Cancer81:519-26.
Kasper et al. (1996) “Immunocytochemical evidence for a modulation of galectin-3 (mac2), a carbohydrate binding protein, in pulmonary fibrosis,”J Pathol. 179:309-316.
Ochieng et al. (2004) “Extracellular functions of galectin-3 ”Glycoconj J. 19:527-535.
Sano et al.(2003) “Critical role of galectin-3 in phagocytosis by macrophages,”J Clin Invest. 112:389-397.
Ahmed et al. (2007) “Advanced Glycation Endproducts: What is their relevance to diabetic complications?”Diabetes, Obesity and Metabolism9(3): 233-245.
Andre et al. (2001) “Wedgelike Glycodendrimers as Inhibitors of Binding of Mammalian Galectins to Glycoproteins, Lactose Maxiclusters, and Cell Surface Glycoconjugates,”Chembiochem2: 822-830.
Aragno et al. (2005) “Up-regulation of advanced glycated products receptors in the brain of diabetic rats is prevented by antioxidant treatment,”Endocrinology146(12): 5561-5567.
Aragno et al. (2006) “Oxidative Stress-Dependent Impairment of Cardiac-Specific Transcription Factors in Experimental Diabetes,”Endocrinology147(12): 5967-5974.
Bandman et al. (2002) “Complexity of Inflammatory Responses in Endothelial Cells and Vascular Smooth Muscle Cells Determined by Microarray Analysis,”Ann. NY. Acad. Sci. 975: 77-90.
Bender MedSystems product information and manual for enzyme-linked immunosorbent assay for quantitative detection of human Galectin-3, BMS279/2, dated Aug. 24, 2006, 32 pages.
Bohlender et al. (2005) “Advanced glycation end products and the kidney,” American Journal of Physiology: Renal Physiology 289: F645-F659.
Bolli (2002) “Clinical strategies for controlling peaks and valleys: type 1 diabetes ”IJCP10 pages.
Boluyt et al. (1995) “The ageing spontaneously hypertensive rat as a model of the transition from stable compensated hypertrophy to heart failure,”European Heart Journal19-30.
Boluyt et al. (1995) “The lonely failing heart: a case for ECM genes,”Cardiovascular Research835-340.
Boluyt et al. (2000) “Matrix gen expression and decompensated heart failure: The aged SHR model,”Cardiovascular Research239-249.
Broers et al. (1999) “Dynamics of the nuclear lamina as monitored by GFP-tagged A-type lamins,”Journal of Cell Science3463-3475.
Brooks et al. (1997) “Captopril Modifies Gene Expression in Hypertrophied and Failing Hearts of Aged Spontaneously Hypertensive Rats,”Hypertension1362-1368.
Cameselle-Teijeiro et al. (2005) “Cystic tumor of the atrioventricular node of the heart appears to be the heart equivalent of the solid cell nests (ultimobranchial rests) of the thyroid,”American Journal of Clinical Pathology123(3): 369-375.
Cheng et al. (2007) “Differential neuroprotective effects of a minocycline-based drug cocktail in transient and permanent focal cerebral ischemia,”Experimental Neurology204(1): 433-442.
Cherayil et al. (1990) “Molecular cloning of a human macrophage lectin specific for galactose,”Proc. Natl. Acad. Sci. USA7324-7328.
Cleutjens et al. (1995) “Collagen Remodeling after Myocardial Infarction in the Rat Heart,”American Journal of Pathology325-338.
Cleutjens et al. (1999) “Thrombospondin 2 Deficiency in Mice Results in Cardiac Rupture Early after Myocardial Infarction,”Circulation(abstract).
Gabius (1990) “Influence of Type of Linkage and Spacer on the Interaction of beta-Galactoside-Binding Proteins with Immobilized Affinity Ligands,”Analytical Biochemistry91-94.
Giordanengo et al. (2001) “Anti-galectin-1 autoantibodies in human Trypansosoma cruzi infection: differential expression of this β-galactosie-binding protein in cardiac Chagas' disease,”Clinc. Exp. Immunology266-273.
Hein et al. (2003) “Progression From Compensated Hypertrophy to Failure in the Pressure-Overloaded Human Heart: Structural Deterioration and Compensatory Mechanism,”Journal of the American Heart Association984-991.
International Preliminary Report for International Application No. PCT/EP2004/10879, mailed Sep. 20, 2005.
Iurisci et al. (2000) “Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients,”Clinical Cancer Research6:1389-1393.
Kankova et al. (2005) “Haplotype Analysis of the RAGE gene: Identification of a Haplotype Marker for Diabetic Nephropathy in Type 2 Diabetes Mellitus,”Nephrology, Dialysis, Transplantation20(6): 1093-1102.
Karlsen et al.(2006) “Immune-mediated beta-cell destruction in vitro and in vivo—A pivotal role for galectin-3,”Biochemical and Biophysical Research Communications344(1): 406-415.
Kostin et al. (2003) “Mycocytes Die by Multiple Mechanisms in Failing Human Hearts,”Circulation Research1-10.
Liehn et al. (2005) “CCR5-but not CCR1-deficiency protects against neointima formation in apolipoprotein E-deficient mice,”European Heart Journal26(Suppl 1): 239.
Liu et al. (2009) “Angiotensin-converting Enzyme is a Modifier of Hypertensive End Organ Damage,”Journal of Biological Chemistry284(23): 15564-15572.
Lok et al. (2007) “Galectin-3, a novel marker of macrophage activity, predicts outcome in patients with stable chronic heart failure,”Journal of the American College of Cardiology49(9) Suppl. A: 98A.
Lorell et al. (2000) “Left Ventricular Hypertrophy: Pathogenesis, Detection, and Prognosis,”Circulation470-479.
Luft et al. (1999) “
Counts Gary W
Goodwin & Procter LLP
Universiteit Maastricht
Yu Melanie J
LandOfFree
Method for identifying a subject at risk of developing heart... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for identifying a subject at risk of developing heart..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for identifying a subject at risk of developing heart... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4314389